Total Payments
$154,180
2024 Payments
$5,529
Companies
27
Transactions
128
Medicare Patients
743
Medicare Billing
$146,042
Payment Breakdown by Category
Consulting$127,063 (82.4%)
Research$10,545 (6.8%)
Other$8,167 (5.3%)
Travel$6,116 (4.0%)
Food & Beverage$2,176 (1.4%)
Education$113.04 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $127,063 | 58 | 82.4% |
| Unspecified | $10,545 | 8 | 6.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $6,667 | 4 | 4.3% |
| Travel and Lodging | $6,116 | 20 | 4.0% |
| Food and Beverage | $2,176 | 35 | 1.4% |
| Honoraria | $1,500 | 1 | 1.0% |
| Education | $113.04 | 2 | 0.1% |
Payments by Type
General
$143,635
120 transactions
Research
$10,545
8 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $45,282 | 37 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $20,413 | 13 | $0 (2019) |
| Amgen Inc. | $14,927 | 7 | $0 (2023) |
| ABBVIE INC. | $13,734 | 11 | $0 (2024) |
| Merck Sharp & Dohme Corporation | $9,250 | 6 | $0 (2021) |
| Millennium Pharmaceuticals, Inc. | $7,455 | 2 | $0 (2017) |
| PFIZER INC. | $5,540 | 4 | $0 (2022) |
| Bayer HealthCare Pharmaceuticals Inc. | $5,080 | 2 | $0 (2021) |
| E.R. Squibb & Sons, L.L.C. | $4,962 | 7 | $0 (2019) |
| Seattle Genetics, Inc. | $4,611 | 6 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $5,529 | 9 | ABBVIE INC. ($2,100) |
| 2023 | $20,482 | 18 | Amgen Inc. ($7,788) |
| 2022 | $18,433 | 11 | AstraZeneca Pharmaceuticals LP ($11,120) |
| 2021 | $36,624 | 24 | AstraZeneca Pharmaceuticals LP ($11,303) |
| 2020 | $12,935 | 7 | AstraZeneca Pharmaceuticals LP ($5,480) |
| 2019 | $29,345 | 29 | Takeda Pharmaceuticals U.S.A., Inc. ($14,843) |
| 2018 | $6,672 | 8 | Takeda Pharmaceuticals U.S.A., Inc. ($5,570) |
| 2017 | $24,161 | 22 | AbbVie, Inc. ($9,009) |
All Payment Transactions
128 individual payment records from CMS Open Payments — Page 1 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/30/2024 | CATALYST PHARMACEUTICALS, INC. | FIRDAPSE (Drug) | Honoraria | Cash or cash equivalent | $1,500.00 | General |
| Category: NEUROLOGY | ||||||
| 11/22/2024 | Novartis Pharmaceuticals Corporation | MEKINIST (Drug) | Food and Beverage | In-kind items and services | $13.87 | General |
| Category: Oncology | ||||||
| 10/11/2024 | ABBVIE INC. | — | Consulting Fee | Cash or cash equivalent | $2,100.00 | General |
| 06/21/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $1,370.00 | General |
| 06/03/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Food and Beverage | In-kind items and services | $135.00 | General |
| Category: Oncology | ||||||
| 05/23/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | In-kind items and services | $129.62 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1 ANTIBODY) VERSUS CEMIPLIMAB MONOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH TUMORS EXPRESSING PD-L1 =50% • Category: ONCOLOGY | ||||||
| 05/21/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $156.58 | General |
| 05/07/2024 | Lilly USA, LLC | — | Education | In-kind items and services | $101.43 | General |
| 02/16/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $22.00 | General |
| Category: Oncology | ||||||
| 10/13/2023 | Amgen Inc. | LUMAKRAS (Drug) | Consulting Fee | Cash or cash equivalent | $3,894.00 | General |
| Category: Oncology | ||||||
| 10/10/2023 | Fosun Pharma USA Inc. | — | Food and Beverage | In-kind items and services | $60.16 | General |
| 09/13/2023 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | Cash or cash equivalent | $20.09 | General |
| Category: Oncology | ||||||
| 08/25/2023 | AVEO Pharmaceuticals, Inc. | FOTIVDA (Drug) | Food and Beverage | In-kind items and services | $18.16 | General |
| Category: Oncology | ||||||
| 07/19/2023 | JAZZ PHARMACEUTICALS INC. | ZEPZELCA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,480.00 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 07/17/2023 | Genentech, Inc. | Alecensa (Biological), Avastin, Gavreto | Food and Beverage | In-kind items and services | $38.48 | General |
| Category: BioOncology | ||||||
| 06/03/2023 | Fosun Pharma USA Inc. | — | Food and Beverage | In-kind items and services | $84.80 | General |
| 05/02/2023 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $3,082.50 | General |
| 04/21/2023 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $685.00 | General |
| 04/10/2023 | AVEO Pharmaceuticals, Inc. | FOTIVDA (Drug) | Food and Beverage | In-kind items and services | $18.30 | General |
| Category: Oncology | ||||||
| 03/17/2023 | AVEO Pharmaceuticals, Inc. | FOTIVDA (Drug) | Food and Beverage | In-kind items and services | $17.37 | General |
| Category: Oncology | ||||||
| 03/15/2023 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | Cash or cash equivalent | $20.50 | General |
| Category: Oncology | ||||||
| 03/09/2023 | Puma Biotechnology, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,275.00 | General |
| 02/22/2023 | Seagen Inc. | — | Consulting Fee | Cash or cash equivalent | $2,250.00 | General |
| 02/08/2023 | Amgen Inc. | LUMAKRAS (Drug) | Consulting Fee | Cash or cash equivalent | $2,596.00 | General |
| Category: Oncology | ||||||
| 02/08/2023 | Amgen Inc. | LUMAKRAS (Drug) | Consulting Fee | Cash or cash equivalent | $1,298.00 | General |
| Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| ONCOLOGY PORTFOLIO CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $4,760 | 3 |
| GEDATOLISIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $780.00 | 1 |
| A PHASE 1, OPEN-LABEL, DOSE-ESCALATION AND COHORT EXPANSION FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY, ACTIVITY AND PHARMACOKINETICS OF REGN3767 ANTI-LAG-3 MAB ADMINISTERED ALONE OR IN COMBINATION WITH REGN2810 ANTI-PD-1 MAB IN PATIENTS WITH ADVANCED MALIGNANCIES | Regeneron Pharmaceuticals, Inc. | $675.28 | 2 |
| A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1 ANTIBODY) VERSUS CEMIPLIMAB MONOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH TUMORS EXPRESSING PD-L1 =50% | Regeneron Pharmaceuticals, Inc. | $129.62 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 148 | 319 | $72,762 | $31,423 |
| 2022 | 4 | 207 | 408 | $93,654 | $40,829 |
| 2021 | 4 | 193 | 373 | $83,770 | $38,821 |
| 2020 | 4 | 195 | 435 | $98,190 | $34,969 |
Total Patients
743
Total Services
1,535
Medicare Billing
$146,042
Procedure Codes
15
All Medicare Procedures & Services
15 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 74 | 217 | $51,646 | $22,770 | 44.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 49 | 77 | $12,166 | $5,344 | 43.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 25 | 25 | $8,950 | $3,309 | 37.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 89 | 253 | $60,214 | $27,329 | 45.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 68 | 105 | $16,590 | $7,153 | 43.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 36 | 36 | $12,888 | $4,972 | 38.6% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 14 | 14 | $3,962 | $1,374 | 34.7% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 81 | 223 | $53,074 | $25,118 | 47.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 79 | 117 | $18,486 | $8,733 | 47.2% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 22 | 22 | $7,876 | $3,267 | 41.5% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 11 | 11 | $4,334 | $1,703 | 39.3% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 88 | 279 | $66,402 | $23,261 | 35.0% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 74 | 123 | $19,434 | $6,803 | 35.0% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 18 | 18 | $6,444 | $2,461 | 38.2% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 15 | 15 | $5,910 | $2,444 | 41.3% |
About Dr. Afshin Dowlati, MD
Dr. Afshin Dowlati, MD is a Hematology & Oncology healthcare provider based in Cleveland, Ohio. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/13/2006. The National Provider Identifier (NPI) number assigned to this provider is 1528084852.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Afshin Dowlati, MD has received a total of $154,180 in payments from pharmaceutical and medical device companies, with $5,529 received in 2024. These payments were reported across 128 transactions from 27 companies. The most common payment nature is "Consulting Fee" ($127,063).
As a Medicare-enrolled provider, Dowlati has provided services to 743 Medicare beneficiaries, totaling 1,535 services with total Medicare billing of $146,042. Data is available for 4 years (2020–2023), covering 15 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Cleveland, OH
- Active Since 07/13/2006
- Last Updated 12/03/2020
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1528084852
Products in Payments
- ALUNBRIG (Drug) $27,867
- IMFINZI (Biological) $17,945
- IMFINZI (Drug) $17,430
- LUMAKRAS (Drug) $10,384
- KEYTRUDA (Biological) $9,250
- Vitrakvi (Drug) $5,080
- ADCETRIS (Biological) $4,611
- ZEPZELCA (Drug) $4,242
- FIRDAPSE (Drug) $1,500
- TAGRISSO (Drug) $1,370
- ONIVYDE (Drug) $1,305
- Nplate (Biological) $1,298
- Alecensa (Biological) $615.66
- Optune (Device) $500.00
- Tepmetko (Drug) $500.00
- LIBTAYO (Biological) $129.62
- FOTIVDA (Drug) $91.05
- Lenvima (Drug) $62.59
- MEKINIST (Drug) $13.87
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Cleveland
Hillard Lazarus, Md, MD
Hematology & Oncology — Payments: $2.5M
Hematology & Oncology $2.5M
Jorge Garcia, Md, MD
Hematology & Oncology — Payments: $765,093
Hematology & Oncology $765,093
Ronald Bukowski, Md, MD
Hematology & Oncology — Payments: $744,876
Hematology & Oncology $744,876
Balazs Halmos, Md, MD
Hematology & Oncology — Payments: $548,525
Hematology & Oncology $548,525
Dr. Dale Shepard, M.d., Ph.d, M.D., PH.D
Hematology & Oncology — Payments: $481,414
Hematology & Oncology $481,414
Bachar Dergham, Md, MD
Hematology & Oncology — Payments: $456,653
Hematology & Oncology $456,653